These data show that activated B cells could inhibit Th17 but promote Th22 cell differentiation in vivo in lupus-prone mice, supporting the notion that activated B cells could be a promising therapeutic method for treating lupus autoimmunity via IL-22. This evidence concerns the gene IL22 and systemic lupus erythematosus.